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Purpose/Objective: To validate the 'mid-position' approach for lung 
tumor motion management in helical tomotherapy with 4D Monte 
Carlo planning simulation, in comparison with conventional ITV. 
Materials and Methods: 8 patients with stage I non-small cell lung 
cancer (NSCLC) treated by SBRT were included, as well as 6 patients 
with stage II-III NSCLC treated by Simultaneous Integrated Boost (SIB) 
and participating in a dose escalation protocol. Prior to treatment, a 
contrast-enhanced CT (CE-CT) and a 4DCT (for SBRT) or a combined 
4D FDG-PET-CT (for SIB) were acquired. The GTV, CTV, and OARs were 
delineated on the CE-CT according to our clinical protocol. Next, 4D 
data were used to generate first the ITV and then the MidP volume in 
its exact time-weighted mean position of the respiratory motion, using 
a validated Morphon non-rigid registration algorithm. The PTVs were 
finally drawn according to the margin formula for geometric 
uncertainties developed by Van Herk et al. and adapted to the 
specific features of lung tumor tomotherapy. For each patient, two 
treatments were planned based on margins derived from the ITV and 
MidP volume. Volumetric and dosimetric parameters, as well as 
conformity indexes were compared with both strategies. Moreover, 
dose distributions were computed using a 4D Monte Carlo (MC) model, 
in order to assess the impact of intra-fraction tumor motion on tumor 
coverage (quantified by D95), with and without the interplay effect. 
Results: For SBRT and SIB patients, the PTVs defined with the ITV 
approach were on average 1.2 times larger than those derived from 
MidP. Consequently, the dose to all the OARs was on average lower 
when using the MidP. Nonetheless, the planned dose conformity to 
TVs was identical between both strategies (0,92 ± 0,03 and 0,84 ± 
0,05 for DICE and Paddick indexes, respectively). For all SBRT 
patients, D95 to the GTV computed from 4D MC dose distributions 
complied within 1% of the planning recommendations when using the 
ITV approach. In contrast, MidP failed to ensure adequate GTV 
coverage in 3 patients. For one patient, the simulated interplay effect 
lowered the D95 to the GTV by 4.35% compared to the planned dose 
distribution (Fig a). Although the interplay effect did not affect the 
two other patients, simulated MC calculations demonstrated 
significant GTV underdosages, with D95 to GTV reduced by 2.16% and 
2.61% compared to the planned doses (Fig b). 4D MC computations are 
ongoing for the SIB group. 
 
  
Conclusions: Compared to the ITV, the MidP strategy significantly 
reduced the PTV and irradiated volumes in all patients. However, if 
MidP could safely be applied in helical tomotherapy in most cases, it 
might lead to insufficient tumor coverage for very small tumors (< 
5cc) with large motion (> 10mm). Those particular cases are indeed 
questioning the fundamental hypothesis underlying the framework of 
the MidP concept. As SIB treatments are usually delivered to large and 
centrally located tumors, MidP might allow for a safe reduction of the 
PTVs and irradiated tissues, although this still needs to be further 
confirmed.  
   
PO-0823   
Intensity modulated treatment plans reoptimization with 
megavoltage cone beam computed tomography dose 
L. Orlandini1, M. Betti1, T. Malatesta2, M. De Liguoro3, L. Cionini3 
1Centro Onccologico Fiorentino, Medical Physics, Firenze, Italy  
2FBF Isola Tiberina, Medical Physics, Roma, Italy  
3Centro Onccologico Fiorentino, Radiation Oncology, Firenze, Italy  
 
Purpose/Objective: The megavoltage cone beam computed 
tomography (MV-CBCT) dose may be considered in the treatment plan 
prescription dose specially for daily image guided radiation therapy 
(IGRT) treatments. The dosimetric differences on target volumes and 
organs at risks obtained optimizing the intensity modulated treatment 
plan (IMRT) with and without the MV-CBCT were investigated for 
clinical cases routinely treated. 
Materials and Methods: A Siemens Medical Solutions, an Artiste™ 
linear accelerators mounting a MV-CBCT device implemented in Philips 
Pinnacle3 Treatment Planning System (TPS) was used for this work. 
Two different type of treatment (head and neck and prostate) 
performed with daily IGRT-IMRT techniques were enrolled. Twenty 
prostate carcinomas and twelve head and neck tumors treatment 
planning were investigated. For each clinical case the dose 
distribution and the DVH due to IMRT alone (TP1), IMRT plus MV-CBCT 
dose (TP2), IMRT optimized including MV-CBCT dose (TP3) were 
examined. Dmean and Dmax were used for target volume comparison and 
dose volume histograms (DVHs) cut off points for organs at risks 
(OARs) comparison. The impact of the MV-CBCT protocol used on the 
integral dose defined as V5Gy was investigated. The CBCT dose 
calculated was assessed with ionization chamber measurements. 
Results: The theoretical treatment plan (TP1) compared with the one 
optimized with the MV CBCT dose (TP3) did not present difference on 
target dose coverage, while if compared with TP2 (treatment plan 
added with MV CBCT dose) a mean increase of 4,1% and 3% were 
obtained for Dmean and Dmax for ORL and prostate treatment 
respectively. The OARs sparing was worsened in both comparison also 
if a better sparing is obtained with TP2. For the parotides glands the 
Dmean percent difference ranged between +8% and 16 % and for the 
V40Gy of the rectum the percent difference was between 1.5 to 8%. 
The comparison between the 8 monitor units (MU) CBCT protocol 
routinely used and the 5 MU and 15 MU protocols showed and 
increased of the V5GY integral dose between 10 to 52 % and 20 to 66% 
for ORL and prostate treatment respectively. The decreased of V5GY 
integral dose obtained with the 5M CBCT protocol ranged between -2 
to –7% for for ORL and between -6 to –13% for prostate cases. 
Conclusions: Prostate and ORL treated with IMRT and IGRT techniques 
may not be performed without the use of the daily CBCT; it is 
therefore essential to integrate the MV-CBCT dose in the patient 
prescription.  
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Purpose/Objective: VMAT is a complex, arc-based treatment 
technique for intensity modulated radiation therapy. For different 
treatment planning systems it has been shown that plan quality is 
comparable to fixed field IMRT. But achieving acceptable plan quality 
is often based on experience of the operator. This analysis compares 
the plan quality of template-based VMAT plans without operator 
interference against fixed field IMRT plans for Elekta linacs using the 
Varian TPS Eclipse on a statistical basis for various main tumour 
regions. 
Materials and Methods: 181 cases were selected for this study 
including 40 cervical and endometrial, 73 head and neck, 12 brain, 11 
breast and 45 prostate cancer cases. The IMRT plans were developed 
in clinical routine over the last three years using Eclipse TPS. VMAT 
plans were generated using a preclinical version of the Eclipse TPS 
including a VMAT optimizer for Elekta linacs. To standardize the 
optimizing process, tumour region specific optimizing templates were 
created. Based on these templates two VMAT plans were generated 
without interference of the operator: with one full arc (1A) and with 
two full arcs (2A), resp. one or two partial arcs for breast cancer 
cases. All plans were evaluated by target coverage, homogeneity and 
conformity; the organs at risk (OAR) were analysed according to plan 
objectives such as mean and maximum doses. If one or more 
objectives were exceeded, a second VMAT plan was created by 
adapting the optimizing constraints once. All evaluation parameters 
were averaged over all patients for each region and compared using 
the Wilcoxon matched-pair signed rank test. 
Results: For template-based 2A plans in 27 cases out of 181 an 
exceeding of the objectives for one or more OAR was found, in 13 
cases an over- or under-dosage in the PTV. For 1A plans 30 cases 
showed an exceeding of the OAR objectives, 25 for the target volume 
coverage. For the additionally modified plans the OAR exceeding was 
reduced to 23 cases for both 2A and 1A; the over- or under-dosage in 
the PTV was reduced to 8 cases for 2A and to 17 for 1A. In comparison 
to the IMRT plans the 1A and 2A plans showed good results concerning 
the target coverage. Small differences between the considered 
techniques can be found which depends on the tumour region. A 
similar behaviour was found for the OAR. But here, the differences 
between the different techniques and tumour regions show a wider 
